After NICE okay, Scots denied access to Vifor’s VeltassaThe Scottish Medicines Consortium (SMC) has ruled that there’s not enough evidence to support NHS funding of Vifor Share XAfter NICE okay, Scots denied access to Vifor’s Veltassahttps://pharmaphorum.com/news/after-nice-okay-scots-denied-access-to-vifors-veltassa/
AstraZeneca to present the latest cardiovascular researchAstraZeneca and MedImmune will present new data from its Cardiovascular, Renal and Metabolism (CVRM) portfolio for the treatment Share XAstraZeneca to present the latest cardiovascular researchhttps://pharmaphorum.com/news/astrazeneca-presents-latest-cardio-research/
AZ’s potassium drug Lokelma finally approved in USAstraZeneca badly needs new drugs on the market as several former blockbusters have been hit by generic competition Share XAZ’s potassium drug Lokelma finally approved in UShttps://pharmaphorum.com/news/azs-lokelma-finally-approved-in-us/
